The Oklahoma Medical Marijuana Authority has issued a mandatory recall for medical marijuana products tested by Greenleaf Labs between April 2023 and July 2025, escalating an issue the agency says has remained unresolved for months.

According to OMMA, the recall covers products tied to testing performed by Greenleaf Labs LLC after the agency previously found inaccuracies involving yeast and mold calculations. State regulators said Greenleaf was ordered to cease operations in August 2025 following a routine inspection that uncovered testing problems affecting roughly 19,000 samples.

OMMA said dispensaries were notified on Aug. 13, 2025 that the affected products had been changed to failed status in the state’s tracking system, and patients were later warned about potentially unsafe products. Although Greenleaf had committed to a voluntary retesting process, OMMA said the company did not timely verify that all affected customers had been properly notified. Regulators say many of the failed products are still being found in dispensary inventories, prompting the mandatory recall announced Thursday.

The agency warned that improperly tested marijuana can pose immediate health risks, particularly if mold and yeast levels exceed state limits. Patients who believe they purchased an affected product are being told to check the batch number on the product packaging or certificate of analysis and compare it to the recall list published by OMMA.

Patients are also being told to dispose of recalled items or contact the dispensary where they were purchased. Anyone who experiences an adverse reaction after using one of the impacted products is urged to contact a physician immediately.

OMMA said dispensaries must immediately audit their inventories to ensure no failed products remain on shelves. Under state rules, recalled products cannot legally be sold, and commercial licensees are responsible for disposing of them and notifying any downstream businesses and affected patients.